| University Manor Health & Reha | |
| 2186 Ambleside Rd, Cleveland, Ohio 44106 | |
| (216) 721-1400 | |
| Name | University Manor Health & Reha |
|---|---|
| Location | 2186 Ambleside Rd, Cleveland, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 149 |
| Occupancy Rate | 88.86% |
| Medicare ID (CCN) | 365832 |
| Legal Business Name | University Manor Healthcare Group, Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1306253703 |
| Address | 2186 Ambleside Dr, Cleveland, OH 44106 |
| Phone Number | 216-721-1400 |
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.
Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
› Verified 7 days ago
| NPI Number | 1760593818 |
| Organization Name | UNIVERSITY MANOR HEALTHCARE GROUP, INC |
| Doing Business As | UNIVERSITY MANOR |
| Address | 2186 Ambleside Dr, Cleveland, OH 44106 |
| Phone Number | 216-721-1400 |
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.
Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
› Verified 7 days ago
| NPI Number | 1962819391 |
| Address | 2186 Ambleside Dr, Cleveland, OH 44106 |
| Phone Number | 216-721-1400 |
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.
Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.
Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $13504 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 27.4 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.33 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 21.77 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.61 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.4 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.99 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.63 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.54 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 47.39 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.35 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.4 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.39 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.83 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 85.19 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.89 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 45.05 | 82.93 |
News Archive
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.
Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).
Low back pain in the elderly is the result of poor "proprioception," or the body's ability to perceive its own position in space, caused by a deterioration of sensory receptors in their muscles called proprioceptors.
› Verified 7 days ago
Franklin Plaza Extended Care Location: 3600 Franklin Boulevard, Cleveland, Ohio 44113 Phone: (216) 651-1600 | |
Rocky River Gardens Rehab And Nursing Ctr Location: 4102 Rocky River Dr, Cleveland, Ohio 44135 Phone: (216) 251-3300 | |
Euclid Beach Healthcare Location: 16101 Euclid Beach Blvd, Cleveland, Ohio 44110 Phone: (216) 486-2300 |